CAS 137339-65-2
:ser-leu-leu-arg-asn-pro-asn-asp-*lys-tyr-glu-
Description :
La substance chimique portant le nom "ser-phe-leu-leu-arg-asn-pro-asn-asp-lys-tyr-glu-" et le numéro CAS 137339-65-2 est un peptide composé d'une séquence spécifique d'acides aminés. Ce peptide présente une combinaison de résidus polaires, non polaires et chargés, qui contribuent à ses propriétés uniques et à ses fonctions biologiques. La présence d'acides aminés tels que la sérine, la phénylalanine, la leucine, l'arginine, l'asparagine, la proline, la lysine, la tyrosine et l'acide glutamique suggère qu'il pourrait jouer un rôle dans divers processus physiologiques, potentiellement y compris des voies de signalisation ou des fonctions structurelles dans les protéines. La séquence indique un potentiel d'interactions avec d'autres biomolécules, influencées par les chaînes latérales des acides aminés constitutifs. De plus, la solubilité, la stabilité et la réactivité du peptide peuvent être affectées par sa longueur et sa composition, ce qui le rend intéressant dans des domaines tels que la biochimie, la pharmacologie et la biotechnologie. D'autres études seraient nécessaires pour élucider son activité biologique spécifique et ses applications potentielles.
Formule :C81H118N20O23
InChI :InChI=1/C81H118N20O23/c1-43(2)34-53(93-71(114)54(35-44(3)4)94-73(116)55(92-67(110)49(83)42-102)36-45-16-7-5-8-17-45)70(113)90-51(21-13-31-88-81(86)87)69(112)98-59(40-64(85)105)79(122)101-33-15-22-61(101)76(119)97-57(39-63(84)104)74(117)96-58(41-66(108)109)75(118)89-50(20-11-12-30-82)68(111)95-56(37-47-24-26-48(103)27-25-47)72(115)91-52(28-29-65(106)107)78(121)100-32-14-23-62(100)77(120)99-60(80(123)124)38-46-18-9-6-10-19-46/h5-10,16-19,24-27,43-44,49-62,102-103H,11-15,20-23,28-42,82-83H2,1-4H3,(H2,84,104)(H2,85,105)(H,89,118)(H,90,113)(H,91,115)(H,92,110)(H,93,114)(H,94,116)(H,95,111)(H,96,117)(H,97,119)(H,98,112)(H,99,120)(H,106,107)(H,108,109)(H,123,124)(H4,86,87,88)/t49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m0/s1
SMILES :CC(C)C[C@@H](C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC(=N)O)C(=O)N1CCC[C@H]1C(=N[C@@H](CC(=N)O)C(=N[C@@H](CC(=O)O)C(=N[C@@H](CCCCN)C(=N[C@@H](Cc1ccc(cc1)O)C(=N[C@@H](CCC(=O)O)C(=O)N1CCC[C@H]1C(=N[C@@H](Cc1ccccc1)C(=O)O)O)O)O)O)O)O)O)O)N=C([C@H](CC(C)C)N=C([C@H](Cc1ccccc1)N=C([C@H](CO)N)O)O)O
Synonymes :- Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
4 produits concernés.
TRAP-14
CAS :Cloning and expression of a functional human thrombin receptor have revealed a protein with seven transmembrane domains and a large extracellular amino-terminal extension. Thrombin cleaves within this extension, thereby creating a new receptor amino-terminus that functions as a tethered ligand and activates the receptor. A 14-amino acid peptide mimicking this new amino-terminus has been found to be a potent thrombin receptor activator as well as an effective agonist for platelet activation.Formule :C81H118N20O23Degré de pureté :98.1%Couleur et forme :WhiteMasse moléculaire :1739.95TRAP-14 trifluoroacetate salt
CAS :TRAP-14 is a conformationally restricted peptide that binds to the thrombin receptor. TRAP-14 also has a biocompatible polymer backbone that can be used in vivo as an implant. The TRAP-14 peptide has been shown to inhibit thrombin activity and inhibit the expression of basic fibroblast growth factor. In addition, this drug showed an ability to suppress autoimmune diseases in vivo by blocking Ca2+ release from the cytosol. This drug also showed inhibition of polymerase chain reaction (PCR) amplification and increased the specificity of PCR for DNA sequences containing polyvinyl disulfide bonds.Formule :C81H118N20O23Degré de pureté :Min. 95%Masse moléculaire :1,739.92 g/molSER-PHE-LEU-LEU-ARG-ASN-PRO-ASN-ASP-LYS-TYR-GLU-PRO-PHE
CAS :Formule :C81H118N20O23Degré de pureté :97%Couleur et forme :SolidMasse moléculaire :1739.9238H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-OH
CAS :<p>Hypertension is a common condition that affects millions of people worldwide. It is characterized by an elevated blood pressure and the subsequent damage to the heart, kidneys, and other tissues. Metyrapone is a drug that inhibits the synthesis of corticosteroids from cholesterol in the adrenal glands. It was shown to reduce blood pressure in vivo by blocking the formation of cytosolic calcium and subsequent release of vasopressin. The use of metyrapone as a hypertension treatment has been limited due to its side effects on the liver. A new model system using basic fibroblasts (BF) instead of liver cells has been developed to study this drug's effects on hypertension without causing liver lesions. This model has proven successful for other drugs with similar biological properties, such as Hytrinol, which also blocks corticosteroid synthesis from cholesterol but does not cause liver lesions. The BF system can be used for testing new drugs that are selective for PAR1 receptors, which are</p>Formule :C81H118N20O23Degré de pureté :Min. 95%Masse moléculaire :1,739.96 g/mol


